A Study to Evaluate the Safety, Tolerability and PK of SK-08 — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study to Evaluate the Safety, Tolerability and PK of SK-08 — Stella

Home/Chronic Kidney Disease(CKD)/

View on ClinicalTrials.gov

Recruiting

Back to Chronic Kidney Disease(CKD) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The First Affiliated Hospital，Zhejiang University, Hangzhou, Zhejiang

Key details

Phase

Early testing

Sponsor

Consun Pharmaceutical Group

Enrollment target

~48 participants

Started

March 2025

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 45 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.